Find a list of your saved stories here

"Best Contract Research Organization" & "Best Clinical Trial Network and Site"

Save Story

Save stories to read later

Estimated read time: 2-3 minutes

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.





Accelovance Nominated for TWO 2014 Vaccine Industry Excellence (ViE)


ROCKVILLE, Md., March 6, 2014 /PRNewswire-USNewswire/ -- Accelovance,

a therapeutically focused clinical research organization (CRO), has

been named a finalist for two Vaccine Industry Excellence (ViE)

Awards, with nominations for "Best Contract Research Organization" and

"Best Clinical Trial Network and Site."

This is the seventh consecutive year Accelovance has been honored as

an award nominee at the World Vaccine Congress, winning for "Best

Contract Research Organization" in 2009, 2010, and 2011, as well as

receiving a "Highly Recommended" distinction in 2013.

"We're honored to be nominated for these two awards, which highlight

the continued depth and breadth of our leadership and experience

within the conduct of vaccine trials. Our dedication to serving the

needs and advancing the research of Sponsors in this important

therapeutic area continues to be validated by this global Conference

distinction," commented Stephen J. Trevisan, Accelovance President and

Chief Executive Officer.

Accelovance will be evaluated by an international panel for quality of

services, performance, client satisfaction, Sponsor relationships, and

the overall value brought to study Sponsors. Accelovance is well known

within the industry for its experience in managing vaccine trials, for

successful clinical oversight, patient enrollment and retention, and

for providing full service solutions to Sponsors. Award winners will

be announced at the 14th Annual World Vaccine Congress being held in

Washington, D.C.March 24-26, 2014.

About Accelovance

Accelovance is an award-winning, niche CRO focused primarily in

vaccines, oncology, and general medicine. Accelovance operates four

core service divisions; a full-service Contract Research Organization,

Site Management Organization, Patient Recruitment, and Call Center

that positively impact the advancement of clinical research. As a

clinical services provider to the pharmaceutical and biotech

industries, Accelovance offers comprehensive services including

management and implementation of Phase I-IV clinical trials, patient

recruitment/retention solutions, and a Clinical Call Center that can

assist in recruitment, retention, and post-marketing surveillance.

Established in 2005 with a corporate mission to improve the quality

and predictability in clinical research, Accelovance is a privately

held company headquartered in Rockville, Maryland. Accelovance has

made significant strides in the industry by combining strong business

and operational perspective with clinical and medical expertise.

Press Contact: Michael Keens, VP Business Development 240.238.4941 Twitter: @Accelovance

Logo -

SOURCE Accelovance

-0- 03/06/2014


/Web Site:

CO: Accelovance

ST: Maryland District of Columbia




-- DC78163 --

0000 03/06/2014 14:00:00 EDT

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent Business stories

Related topics

The Associated Press


    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the Trending 5.
    By subscribing, you acknowledge and agree to's Terms of Use and Privacy Policy.

    KSL Weather Forecast